137 related articles for article (PubMed ID: 37755141)
1. Real world experience with conversion from valganciclovir to letermovir for cytomegalovirus prophylaxis: Letermovir reverses leukopenia and avoids mycophenolate dose reduction.
Jorgenson MR; Descourouez JL; Saddler CM; Smith JA; Odorico JS; Rice JP; Mandelbrot DA
Clin Transplant; 2023 Dec; 37(12):e15142. PubMed ID: 37755141
[TBL] [Abstract][Full Text] [Related]
2. Conversion from cytomegalovirus universal prophylaxis with valganciclovir to the preemptive monitoring approach to manage leukopenia after kidney or pancreas transplantation.
Jorgenson MR; Wong C; Descourouez JL; Saddler CM; Smith JA; Mandelbrot DA
Transpl Infect Dis; 2021 Aug; 23(4):e13617. PubMed ID: 33866643
[TBL] [Abstract][Full Text] [Related]
3. Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight-based dosed valganciclovir prophylaxis.
Liverman R; Serluco A; Nance G; George R; Rodriguez DS; Deshpande S; Mao C; Garro R; Yildirim I
Pediatr Transplant; 2023 Jun; 27(4):e14493. PubMed ID: 36945819
[TBL] [Abstract][Full Text] [Related]
4. Use of letermovir-valganciclovir combination as a step-down treatment after foscarnet for ganciclovir-resistant CMV infection in kidney transplant recipients.
Rho E; Näf B; Müller TF; Wüthrich RP; Schachter T; von Moos S
Clin Transplant; 2021 Nov; 35(11):e14401. PubMed ID: 34181768
[TBL] [Abstract][Full Text] [Related]
5. Letermovir for pre-emptive cytomegalovirus therapy after allogeneic hematopoietic cell transplantation.
Kaur R; Purtill D; Cooney J; Cannell P; Wright M; Copeland TS; McGuire M; Boan P
Transpl Infect Dis; 2023 Nov; 25 Suppl 1():e14147. PubMed ID: 37676725
[TBL] [Abstract][Full Text] [Related]
6. Letermovir conversion after valganciclovir treatment in cytomegalovirus high-risk abdominal solid organ transplant recipients may promote development of cytomegalovirus-specific cell mediated immunity.
Jorgenson MR; Kleiboeker H; Garg N; Parajuli S; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA
Transpl Infect Dis; 2022 Feb; 24(1):e13766. PubMed ID: 34799964
[TBL] [Abstract][Full Text] [Related]
7. Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial.
Limaye AP; Budde K; Humar A; Vincenti F; Kuypers DRJ; Carroll RP; Stauffer N; Murata Y; Strizki JM; Teal VL; Gilbert CL; Haber BA
JAMA; 2023 Jul; 330(1):33-42. PubMed ID: 37279999
[TBL] [Abstract][Full Text] [Related]
8. Letermovir prophylaxis in solid organ transplant-Assessing CMV breakthrough and tacrolimus drug interaction.
Winstead RJ; Kumar D; Brown A; Yakubu I; Song C; Thacker L; Gupta G
Transpl Infect Dis; 2021 Aug; 23(4):e13570. PubMed ID: 33469975
[TBL] [Abstract][Full Text] [Related]
9. Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil.
Brum S; Nolasco F; Sousa J; Ferreira A; Possante M; Pinto JR; Barroso E; Santos JR
Transplant Proc; 2008 Apr; 40(3):752-4. PubMed ID: 18455007
[TBL] [Abstract][Full Text] [Related]
10. Letermovir for Cytomegalovirus prophylaxis in pediatric hematopoietic stem cell transplantation.
Chen TT; David AP; Barthelmess EK; MacBrayne CE
Pediatr Blood Cancer; 2023 Nov; 70(11):e30608. PubMed ID: 37548491
[TBL] [Abstract][Full Text] [Related]
11. Real-life use of letermovir prophylaxis for cytomegalovirus in heart transplant recipients.
Saltiel G; Faure E; Assaf A; Chopin MC; Moreau F; Faure K; Goeminne C; Vuotto F
Clin Transplant; 2024 May; 38(5):e15327. PubMed ID: 38686437
[TBL] [Abstract][Full Text] [Related]
12. Letermovir for cytomegalovirus prophylaxis in high-risk heart transplant recipients.
Golob S; Batra J; DeFilippis EM; Uriel M; Carey M; Gaine M; Mabasa A; Fried J; Raikelkar J; Restaino S; Hi Lee S; Latif F; Yuzefpolskaya M; Colombo PC; Choe J; Majure D; Jennings D; Pereira MR; Clerkin K; Sayer G; Uriel N
Clin Transplant; 2022 Dec; 36(12):e14808. PubMed ID: 36086937
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic letermovir decreases cytomegalovirus reactivation after stem cell transplantation: a single-center real-world evidence study.
Serio B; Giudice V; Guariglia R; Fontana R; Pezzullo L; Martorelli MC; Ferrara I; Mettivier L; D'Addona M; Vaccaro E; Langella M; Selleri C
Infez Med; 2021 Mar; 29(1):102-113. PubMed ID: 33664179
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus in renal transplant recipients from living donors with and without valganciclovir prophylaxis and with immunosuppression based on anti-thymocyte globulin or basiliximab.
Andrade-Sierra J; Heredia-Pimentel A; Rojas-Campos E; Ramírez Flores D; Cerrillos-Gutierrez JI; Miranda-Díaz AG; Evangelista-Carrillo LA; Martínez-Martínez P; Jalomo-Martínez B; Gonzalez-Espinoza E; Gómez-Navarro B; Medina-Pérez M; Nieves-Hernández JJ
Int J Infect Dis; 2021 Jun; 107():18-24. PubMed ID: 33862205
[TBL] [Abstract][Full Text] [Related]
15. Use of Letermovir for Primary and Secondary Cytomegalovirus Prophylaxis in Abdominal Organ Transplantation: A Single Center Experience.
Ibrahim D; Byrns J; Maziarz E; Alexander BD; Saullo JL
J Pharm Pract; 2024 Jun; 37(3):770-779. PubMed ID: 37280011
[No Abstract] [Full Text] [Related]
16. Five-year single-center analysis of cytomegalovirus viremia in kidney transplant recipients and possible implication for novel prophylactic therapy approaches.
Trappe M; Affeldt P; Grundmann F; Kann M; Koehler FC; Müller RU; Stippel D; Kaiser R; Knops E; Heger E; Steger G; Klein F; Kurschat C; Di Cristanziano V
Transpl Infect Dis; 2024 Feb; 26(1):e14233. PubMed ID: 38180168
[TBL] [Abstract][Full Text] [Related]
17. Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease.
Taber DJ; Ashcraft E; Baillie GM; Berkman S; Rogers J; Baliga PK; Rajagopalan PR; Lin A; Emovon O; Afzal F; Chavin KD
Transpl Infect Dis; 2004 Sep; 6(3):101-9. PubMed ID: 15569225
[TBL] [Abstract][Full Text] [Related]
18. Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: a systematic review and meta-analysis.
Kalil AC; Mindru C; Botha JF; Grant WJ; Mercer DF; Olivera MA; McCartan MA; McCashland TM; Langnas AN; Florescu DF
Liver Transpl; 2012 Dec; 18(12):1440-7. PubMed ID: 22887929
[TBL] [Abstract][Full Text] [Related]
19. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
Aryal S; Katugaha SB; Cochrane A; Brown AW; Nathan SD; Shlobin OA; Ahmad K; Marinak L; Chun J; Fregoso M; Desai S; King C
Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus infection in heart transplantation: A single center experience.
Echenique IA; Angarone MP; Rich JD; Anderson AS; Stosor V
Transpl Infect Dis; 2018 Aug; 20(4):e12896. PubMed ID: 29602266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
